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Abstract
Sepsis  is  almost  invariably  associated  with  haemostatic  abnormalities  ranging  from 
subclinical  activation  of  blood  coagulation  (hypercoagulability),  which  may  contribute  to 
localized venous thromboembolism, to acute disseminated intravascular coagulation (
characterized  by  massive  thrombin  formation  and  widespread  microvascular  thrombosis, 
partly  responsible  of  the  multiple  organ  dysfunction  syndrome  (MODS),  and  subsequent 
consumption  of  platelets  and  coagulation  proteins  causing,  in  most  severe  cases,
manifestations. There is general agreement that the key event underlying this life
sepsis complication is the overwhelming inflammatory host response to the infectious agent 
leading to the overexpression of inflammatory mediators. Mec
with the micro-organism and its derivatives, causes DIC by 1) up
molecules, primarily tissue factor (TF), which is produced mainly by stimulated monocytes
macrophages  and  by  specific  cells  in  ta
anticoagulant pathways (antithrombin, protein C pathway, tissue factor pathway inhibitor), 
which is orchestrated mainly by dysfunctional endothelial cells (ECs); and 3) suppression of 
fibrinolysis due to increased plasminogen activator inhibitor
to  thrombin-mediated  activation  of  thrombin
Notably,  clotting  enzymes  non  only  lead  to  microvascular  thrombosis  but  can  also  elicit 
cellular responses that amplify the inflammatory reactions. Inflammatory mediators can also 
cause,  directly  or  indirectly,  cell  apoptosis  or  necrosis  and  recent  evidence  indicates  that 
products  released  from  dead  cells,  such  as  nuclear  proteins  (particularly  extracellu
histones), are able to propagate further inflammation, coagulation,  cell death and MODS. 
These  insights into the pathogenetic  mechanisms of DIC and MODS  may have  important 
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Sepsis  is  almost  invariably  associated  with  haemostatic  abnormalities  ranging  from 
subclinical  activation  of  blood  coagulation  (hypercoagulability),  which  may  contribute  to 
localized venous thromboembolism, to acute disseminated intravascular coagulation (
characterized  by  massive  thrombin  formation  and  widespread  microvascular  thrombosis, 
partly  responsible  of  the  multiple  organ  dysfunction  syndrome  (MODS),  and  subsequent 
consumption  of  platelets  and  coagulation  proteins  causing,  in  most  severe  cases,
manifestations. There is general agreement that the key event underlying this life
sepsis complication is the overwhelming inflammatory host response to the infectious agent 
leading to the overexpression of inflammatory mediators. Mechanistically, the latter, together 
organism and its derivatives, causes DIC by 1) up-regulation of procoagulant 
molecules, primarily tissue factor (TF), which is produced mainly by stimulated monocytes
macrophages  and  by  specific  cells  in  target  tissues;  2)  impairment  of  physiological 
anticoagulant pathways (antithrombin, protein C pathway, tissue factor pathway inhibitor), 
which is orchestrated mainly by dysfunctional endothelial cells (ECs); and 3) suppression of 
ed plasminogen activator inhibitor-1 (PAI-1) by ECs and likely also 
mediated  activation  of  thrombin-activatable  fibrinolysis  inhibitor  (TAFI). 
Notably,  clotting  enzymes  non  only  lead  to  microvascular  thrombosis  but  can  also  elicit 
onses that amplify the inflammatory reactions. Inflammatory mediators can also 
cause,  directly  or  indirectly,  cell  apoptosis  or  necrosis  and  recent  evidence  indicates  that 
products  released  from  dead  cells,  such  as  nuclear  proteins  (particularly  extracellu
histones), are able to propagate further inflammation, coagulation,  cell death and MODS. 
These  insights into the pathogenetic  mechanisms of  DIC and MODS  may have  important 
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES
Coagulation  and 
Department of Biomedical Sciences and Human Oncology, Section of General and Experimental Pathology, 
Prof. Nicola Semeraro, M.D., Ph.D. Dipartimento di Scienze Biomediche e Oncologia 
Policlinico, Piazza G. Cesare, 11. 
semeraro@dimo.uniba.it
Creative  Commons  Attribution  License
which permits unrestricted use, distribution, and reproduction in any medium, provided
Sepsis  is  almost  invariably  associated  with  haemostatic  abnormalities  ranging  from 
subclinical  activation  of  blood  coagulation  (hypercoagulability),  which  may  contribute  to 
localized venous thromboembolism, to acute disseminated intravascular coagulation (DIC), 
characterized  by  massive  thrombin  formation  and  widespread  microvascular  thrombosis, 
partly  responsible  of  the  multiple  organ  dysfunction  syndrome  (MODS),  and  subsequent 
consumption  of  platelets  and  coagulation  proteins  causing,  in  most  severe  cases, bleeding 
manifestations. There is general agreement that the key event underlying this life-threatening 
sepsis complication is the overwhelming inflammatory host response to the infectious agent 
hanistically, the latter, together 
regulation of procoagulant 
molecules, primarily tissue factor (TF), which is produced mainly by stimulated monocytes-
rget  tissues;  2)  impairment  of  physiological 
anticoagulant pathways (antithrombin, protein C pathway, tissue factor pathway inhibitor), 
which is orchestrated mainly by dysfunctional endothelial cells (ECs); and 3) suppression of 
1) by ECs and likely also 
activatable  fibrinolysis  inhibitor  (TAFI). 
Notably,  clotting  enzymes  non  only  lead  to  microvascular  thrombosis  but  can  also  elicit 
onses that amplify the inflammatory reactions. Inflammatory mediators can also 
cause,  directly  or  indirectly,  cell  apoptosis  or  necrosis  and  recent  evidence  indicates  that 
products  released  from  dead  cells,  such  as  nuclear  proteins  (particularly  extracellular 
histones), are able to propagate further inflammation, coagulation, cell death and MODS. 
These  insights into the  pathogenetic  mechanisms of DIC and MODS  may have important Medit J Hemat Infect Dis 2010; 2(3); Open Journal System 
implications for the development of new therapeutic agents that could be potentially useful 
particularly for the management of severe sepsis.
Introduction:  Sepsis  is  a  serious  and  relatively 
common disorder and represents the leading cause 
of  mortality  in  non-coronary  intensive  care  units 
worldwide.  Sepsis  is  almost  invariably  associated 
with  haemostatic  abnormalities  ranging  from 
isolated  thrombocytopenia  and/or  subclinical 
activation  of  blood  coagulation  (hyper-
coagulability),  to  sustained  systemic  clotting 
activation  with  massive  thrombin  and  fibrin 
formation and subsequent consumption of platelets 
and  proteins  of  the  haemostatic  system  (acute 
disseminated  intravascular  coagulation,  DIC).
1
From  a  clinical  standpoint,  isolated 
thrombocytopenia,  which   is  seen mainly in  viral 
infections,  is  only occasionally serious  enough  to 
cause  a  bleeding  diathesis.  Although  it  may  be 
immune mediated, other non immune pathogenetic 
mechanisms might be involved, including decreased 
thrombopoiesis, direct interaction of the virus with 
platelets and increased sequestration by the spleen 
or at the endothelial level due, for instance, to virus-
induced  endothelial  injury.
2 Septic  patients  may 
also  present  with  localized  thrombotic 
manifestations. Several studies, indeed, have shown 
that patients with severe infectious diseases are at 
increased  risk  for  venous  thrombosis  and 
pulmonary  embolism.
3-5 The  most  common  and 
dramatic clinical feature of sepsis-associated DIC, 
however,  is  widespread  thrombosis  in  the 
microcirculation  of different  organs  which  may 
importantly contribute to solitary or multiple organ 
dysfunction. The development of the multiple organ 
dysfunction  syndrome  (MODS)  is  a  major 
determinant  of  mortality  in  sepsis.
1,2,6 Therefore, 
health care providers must be aware of the signs of 
organ  dysfunction  and  specifically  look  for  the 
occurrence of this complication. In fulminant DIC, 
the  consumption  and  subsequent  exhaustion  of 
platelets  and  coagulation  proteins  will  result  in 
simultaneous bleeding of different severity, ranging 
from oozing at arterial or venous puncture sites to 
profuse  haemorrhage  from  various  sites.  DIC  is 
classically associated with Gram negative bacterial 
infections but it can occur with a similar incidence 
in  Gram  positive  sepsis.  Moreover,  systemic 
infections  with  other  micro-organisms,  such  as 
viruses,  Rickettsiae and  even  parasites  (e.g. 
Plasmodium falciparum) may also result in DIC.
6
The pathophysiology of sepsis-associated DIC 
is extremely complex and still represents a matter of 
extensive  investigation.  The  key  event  is  the 
systemic  inflammatory  response  to  the  infectious 
agent.
7,8 The  causative  micro-organisms  express 
unique cellular constituents not found in vertebrate 
animals,  now  referred  to  as  pathogen-associated 
molecular  patterns  (PAMPs),  or  microbial-
associated  molecular  patterns  (for  example 
endotoxin  or  lipopolysaccharide,  LPS).  Moreover, 
during infection, inflammation or stress, host cell-
derived  factors  are  generated  as  “danger  signals” 
(alarmins)  which,  together  with  PAMPs,  are 
referred to as danger-associated molecular patterns 
(DAMPs).  These  elements  are  recognized  via 
specific  receptors  called  pattern  recognition 
receptors  (PRRs),  among  which  the  Toll-like 
receptors (TLRs) and the complement receptors, by 
immune  and  other  host  cells  (monocytes-
macrophages, platelets and endothelial cells among 
others).  The  subsequent  activation  of  specific 
intracellular  signal-transduction  pathways 
eventually results in the synthesis of a number of 
proteins including proinflammatory cytokines. The 
latter,  together with other mediators generated by 
the inflammatory cascade, including those derived 
from  complement  activation,
9 act  in  concert  with 
the micro-organisms and/or their products to trigger 
the  coagulation  pathways,  DIC  and  organ 
dysfunction.
1,10,11 Interestingly,  enzymes  generated 
during  the  clotting cascade  can  also interact with 
specific  cellular  receptors  thus  eliciting  cell 
responses  that  amplify  the  inflammatory 
reactions.
12,13 Inflammation  can  also  result  in  cell 
apoptosis or necrosis
7 and recent evidence indicates 
that  products  released  from  dead  cells,  such  as 
nuclear  proteins,  are  able  to  propagate  further 
inflammation,  coagulation,  cell  death  and  organ 
failure.
7,14,15 This  article  summarizes  current 
knowledge on the pathogenesis of DIC and multiple 
organ dysfunction and the ensuing development of 
potential therapeutics. 
Pathogenesis  of  sepsis-associated  coagulopathy 
and thrombus formation
In sepsis the causative agent and the associated 
inflammatory  response  drive  fibrin  formation  and 
deposition  by  several  simultaneously  acting 
mechanisms  which  include  1)  up-regulation  of 
procoagulant  pathways,  2)  down-regulation  of 
physiological anticoagulants and 3) suppression of 
fibrinolysis.
1,6,11,16Medit J Hemat Infect Dis 2010; 2(3): Open Journal System
Up-regulation  of  procoagulant  pathways: The 
aberrant in vivo expression  of  TF plays a pivotal 
role  in  the activation  of  blood  coagulation  in  the 
setting  of  sepsis  and  endotoxemia.  Indeed  the 
impairment  of  the  TF  pathway  by  various means 
prevents  blood  clotting  abnormalities  (including 
fibrin  deposition  in  target  tissues)  and,  in  some 
models, also the lethal effects of endotoxemia.
11,17-21
Conversely,  inhibition  of  the  contact  system  by 
anti-factor  XII  antibodies, while  preventing  lethal 
hypotension, does not influence the development of 
DIC  in  septic baboo.
22 The  prevention  of 
hypotension, which is most likely mediated by the 
generation of bradykinin, indicates that activation of 
the contact system does take place in sepsis and is 
likely  elicited  not  only  by  the  micro-organism  or 
endotoxin,  as  originally  thought,  but  also  by 
recently  discovered  mechanisms  including 
polyphosphate release by activated platelets and/or 
by bacteria
23,24 and extracellular RNA derived from 
damaged or necrotic cells.
25 The implication of TF 
in  sepsis-associated  DIC  is  also supported by the 
observation that the plasma levels of the protein are 
increased  in  septic  patients  and  are  generally 
associated with raised concentrations of markers of 
clotting activation.
26-29 Moreover, in some studies, a 
significant correlation was found between TF levels 
and organ dysfunction.
27,29
Despite this evidence, the question remains: what is 
cellular source of TF in sepsis? In vitro, several cell 
types  that  are  haemostatically  inactive  under 
normal conditions, when exposed to a number of 
agonists,  may  undergo  profound  functional 
alterations  that  effectively  transform  their 
membrane into a procoagulant surface. The pivotal 
step causing this  shift  is  the synthesis  and/or  the 
expression  of  TF. Endothelial  cells  (ECs)  and 
mononuclear  phagocytes  have  been  most 
extensively studied in this respect (Figure 1). These 
cells  can be induced to synthesize TF  by  a wide 
variety of stimulating agents or conditions that are 
of pathophysiological importance in sepsis (Table 
1).
10,30-39 Of particular relevance are, besides micro-
organisms  and  their  products  (LPS,  the  most 
powerful TF inducer and a major player in Gram 
negative  sepsis;  peptidoglycan  and  lipotheicoic 
acid, involved in Gram positive sepsis, and several 
exotoxins),  the  pro-inflammatory  cytokines  and 
chemokines,
10,33-35 and the more recently discovered 
high mobility group box-1 (HMGB-1),
39 which will 
be discussed later. It is remarkable that the classical 
anti-inflammatory  cytokines,  namely  IL-4,  IL-10, 
IL-13 are able to inhibit TF synthesis induced by 
inflammatory stimuli, providing further support to 
the  close  relationship  between  inflammation  and 
coagulation.
40 Another important mechanism for TF 
induction  is  provided  by  cellular  interactions, 
including the interaction of ECs or monocytes with 
T-lymphocytes,  natural  killer  cells,  activated 
platelets and  smooth  muscle  cells  (SMCs).
33-35
These  cell-cell  interactions  may  occur  through 
different pathways, such as CD40 ligation on ECs 
and  monocytes  by  CD154  (CD40  ligand)-
expressing  cells  (e.g.  T-lymphocytes,  platelets, 
SMCs), binding of P-selectin glycoprotein ligand-1 
(PSGL-1) on monocytes to P-selectin on activated 
platelets  or  ECs  and  the  production  of  soluble 
mediators,  including  cytokines and  unknown 
factors.
33-35,41 The  observation  that  Plasmodium 
falciparum-infected red cells are able to induce TF 
synthesis in ECs through cell-cell contact provides 
a possible mechanism for triggering coagulation in 
DIC associated with parasitic infections. Of note, 
parasitized red cells also participate in the clotting 
amplification phase by supporting the assembly of 
tenase and prothrombinase complexes.
42
ECs  and  monocytes  may  also  exhibit  other 
properties  promoting  coagulation  events  on  their 
surface, including the production of factor V and of 
a factor V activator and the expression of specific, 
though ill defined, membrane receptors for several 
clotting factors,
33,43 whereby they can propagate the 
coagulation  reactions  till  thrombin  formation. 
Interestingly,  several  inflammatory  mediators, 
including  TNF,  pathogenic  micro-organisms,  LPS 
and complement membrane attack complex C5b-9, 
may  amplify  the  tenase  and  the  prothrombinase 
assembly on the cell surface, eventually leading to 
an  increased  rate  of  thrombin  formation.
33,43 This 
effect  is  likely  due  to  the  change  in  membrane 
asymmetry  (exposure  of  anionic  phospholipids, 
especially  phosphatydilserine)  required  for 
activation of prothrombin (and factor X). Thrombin 
formation  on  the  surface  of  monocytes-
macrophages  may  be  further  facilitated  by  some 
properties unique to these cells. Indeed, monocytes 
constitutively express at their surface elastase  and 
cathepsin  G  that  activate  factor  V  to  Va.
43 The 
generated  active  cofactor  remains  bound  to  cell 
membrane, so that, following factor Xa formation, a 
functionally efficient prothrombinase  complex can 
be assembled on the cell surface. In addition, factor 
Va  bound  to  monocytes  is  protected  from 
inactivation  by  activated  protein  C,
44,45 implying 
that factor Va activity remains sustained on the cell 
surface  and  that  down-regulation  of  monocyte 
prothrombinase  is  impaired.  Because  of this 
complex array of procoagulant properties, perturbed 
ECs  and,  especially,  activated  monocytes-
macrophages  may  provide  a  surface  ontoMedit J Hemat Infect Dis 2010; 2(3): Open Journal System
Figure 1. Up-regulation of Tissue Factor (TF) in Sepsis. Infectious agents, their products, and endogenous inflammatory mediators 
induce TF synthesis in various blood cells as well as the release of TF-bearing microparticles from activated or apoptotic cells. The 
latter may fuse with different cells  and make them capable of activating coagulation. Available evidence point to  monocytes-
macrophages as the most important procoagulant cells in sepsis.
which  the  clotting  pathways  are  initiated  and 
propagated, eventually leading to fibrin formation 
in the cell microenvironment. Fibrin, once formed, 
might function as  a modulator of the coagulation 
response  by  its  ability  to  down-regulate  the  TF 
response  of monocytes  to  LPS  or  other 
inflammatory stimuli.
46
More  recent  in  vitro  studies  have  reported  TF 
expression  by  other  blood  cells,  namely  human 
polymorphonuclear  leukocytes  (neutrophils  and 
eosinophils)  and  platelets  (Figure 1).  Neutrophils 
produce and express functional TF in response to 
inflammatory agents (C5a, bacterial peptide fMLP, 
P-selectin)
47,48 while  eosinophils  contain 
preferentially  in  their  specific  granules  preformed 
TF, which is translocated to the cell membrane upon 
stimulation with platelet activating factor (PAF) or 
with PAF plus GM-CSF.
49 Other studies, however, 
found  that  neither  neutrophils  nor  eosinophils 
express  TF  but  can  acquire  TF  by  binding 
monocyte-derived  microparticles  (MPs).
50-52
Different  groups  have  described  the  presence  of 
appreciable amounts of TF also in human platelets 
and its translocation in the functionally active form 
to the cell surface in response to classical platelet 
agonists such as collagen,  ADP and thrombin.
53,54
As  to  the  origin  of  platelet  TF,  quiescent  and 
stimulated  platelets  have  been  shown  to  express 
variable  levels  of  TF  mRNA  and  protein.
54,55
Moreover,  Schwertz  et  al.
56 demonstrated  that 
human  platelets  contain  TF  pre-mRNA  and  that 
upon  activation  this  is  spliced  into  mRNA  and 
translated  into  protein.  Again,  however,  other 
groups failed to detect any TF protein or activity on 
resting  or  calcium  ionophore-stimulated  human 
platelets.
57,58 Therefore,  TF  expression  by  human 
platelets  and  polymorphonuclear  leukocytes 
remains controversial.
In addition to triggering and propagating blood 
clotting,  ECs,  monocytes-macrophages  and  other 
cells  may  support  coagulation  by  yet  another 
mechanism, namely the formation of microparticles 
(MPs) (Figure 1). Indeed, cell activation by several 
inflammatory stimuli, as well as cell apoptosis, is 
accompanied by the formation and release into the 
extra-cellular  space  of  fragments  of  their  plasma 
membrane named MPs or microvesicles that retain 
the properties of the cells of origin, among which 
TF  and  anionic  phospholipids.
35,59 Interestingly, 
these MPs can be transferred to the surface of other 
cells via  adhesive  receptors (for instance  PSGL-1 
on  leukocyte-derived  MPs  and  P-selectin  on Medit J Hemat Infect Dis 2010; 2(3): Open Journal System
activated  platelets  or  ECs)  and  this  interaction 
results in increased TF activity.
35,59 In this way, MP-
bearing cells too become capable of triggering and 
propagating coagulation.
Although all mentioned cells might contribute 
to  the  aberrant  in  vivo  expression  of  TF,    most 
available  studies  point  to  activated  monocytes-
macrophages  as  the  main  triggers  of  blood 
coagulation during sepsis or endotoxemia. Indeed, 
monocytes-macrophages of different origin (blood, 
spleen, peritoneal, alveolar, marrow) obtained from 
animals treated with endotoxin or bacteria express 
strong  TF  activity.
17,33,60-64 Studies  in  different 
animal  models  of  endotoxemia  have  shown 
increased TF expression in important target organs 
in which fibrin deposition is often observed during 
DIC,  namely  lung,  kidney,  liver,  spleen  and 
brain.
17,61,63-65At  cellular  level  TF  was  detected 
rather  frequently  in  monocytes  present  in  the 
microcirculation and in macrophages infiltrating the 
involved  tissues
64-66and,  in  some  studies,  also  in 
tissue cells, e.g. alveolar epithelial and alveolar type 
II cells, tubular  and/or  glomerular epithelial  cells, 
and  in  astrocytes.
61,63,64,67 In  addition,  a  selective 
genetic  deficiency  of  TF  expression  by 
hematopoietic cells as  well  as the  deletion  of  TF 
gene  in  myeloid  cells  was  found  to  reduce  LPS-
induced coagulation, inflammation, and mortality in 
mice.
20,68,69 Increased  expression  of  monocyte-
macrophage  TF  has  been also  documented  in 
human  beings,  in  particular  in  healthy  volunteers 
after  administration  of  low-dose  endotoxin,
70,71 in 
septic patients and other conditions with associated 
endotoxemia  (e.g.  obstructive  jaundice),
62,72,73 and 
in  patients  with  peritonitis (in  peritoneal 
macrophages)  or  acute  respiratory  distress 
syndrome  (in  broncho-alveolar  lavage,  BAL, 
fluid).
62,74 Interestingly, in some studies, monocyte 
TF  was  related  with  blood  clotting  activation, 
severe organ dysfunction and lethal outcome.
62,72,73
Surprisingly, and in contrast with the abundant in 
vitro evidence, ECs were negative for TF in most 
animal studies,
61,63,65,67 with few exceptions.
64,75,76 In 
one study TF expression was found in ECs within 
the splenic microvasculature of septic baboons but 
not in ECs of pulmonary vessels.
64 Others observed 
the expression of TF activity on intact aortic ECs of 
endotoxin-treated rabbits.
75 More recently, Lupu et 
al.
76 observed TF protein and activity especially on 
ECs at branch points of the aorta of septic baboons 
and  suggested  that  site-dependent  endothelial 
heterogeneity  coupled  with  rheological  factors 
might  influence  the  focal  vascular  procoagulant 
response  to  sepsis. However,  the  observation that 
the  presence  of  TF  on  ECs  was  restricted  to 
granular  structures  some  of  which  were  also 
positive  for  the  leukocyte  marker  PSGL-1  would 
suggest that leukocyte-derived MPs may deliver TF 
to activated ECs in vivo.
76 These discrepancies in 
the  detection  of    TF  expression  on  ECs  in  vivo 
during  sepsis  and  endotoxemia  might  be  due  to 
different causes including the relative sensitivity of 
the TF assays, the heterogeneous expression of TF 
possibly  linked  to  vascular  bed-specific  response 
and  species-specific  differences  in  vascular 
response to inflammatory stimuli. Recent findings 
indicate that the deletion of the TF gene in ECs had 
no significant effect on activation of coagulation in 
endotoxemic mice.
69
Another source of tissue factor in vivo might be 
polymorphonuclear  cells,  whose  inappropriate 
activation  and  positioning  within  the 
microvasculature  strongly  contributes  to  the 
pathological  manifestations  of  multiple  organ 
failure.
77 Indeed, TF-positive neutrophils have been 
observed in the circulation of septic or endotoxemic 
animals.
76,78 However, de Vaard et al.
79 showed that 
TF-positive granulocytes infiltrating organs do not 
express  TF  mRNA  in  a  mouse  model  of 
endotoxemia suggesting that they can acquire TF by 
binding monocyte-derived MPs.
Platelets most likely play a pivotal role in the 
pathogenesis of coagulation abnormalities in sepsis 
because they can be activated by proinflammatory 
mediators,  such  as  PAF  and  thrombin,  and,  once 
activated,  may  amplify  thrombin  generation  by 
providing  the  anionic  phospholipid  surface  onto 
which coagulation reactions occur.
11 Moreover, by 
expressing  P-selectin  on  their  surface  and/or  by 
releasing soluble P-selectin, platelets may enhance 
the expression of TF on monocytes.
80 As to the role 
of platelet TF, a recent study in a mouse model of 
endotoxemia failed to detect either TF pre-mRNA 
or  RNA  in  unstimulated  or  activated  mouse 
platelets.  Moreover,  deletion  of  the  TF  gene  in 
megakaryocytes  had no effect on clotting activation 
in endotoxemic mice.
69 On the other hand, freshly-
isolated  platelets  from  septic  patients  more 
frequently  expressed  mature  TF  mRNA  and  had 
increased levels of TF protein compared to platelets 
isolated  from  healthy  controls.
69 However,  it  is 
likely that some of the TF protein associated with 
platelets in septic patients derives from the binding 
of  leukocyte-derived  MPs.
69 Although  these  data 
suggest  that  platelets  may  participate  in  the 
activation  of  coagulation  during  sepsis,  the  direct 
involvement  of  platelet  TF  synthesis  remains 
controversial.
There are additional sources of TF that might 
contribute  to  coagulation  activation  in  sepsis, as Medit J Hemat Infect Dis 2010; 2(3): Open Journal System
Figure  2. Anticoagulant  properties  of  endothelial  cells.  Heparan-sulphate  (HS)  is  expressed  on  the  endothelial  surface  and 
accelerates  the  interaction  between  antithrombin  (AT)  and  its  target  enzymes,  among  which  factor  Xa  and  thrombin  (IIa). 
Thrombomodulin (TM) and endothelial protein C receptor (EPCR) are also membrane proteins and are involved in protein C (PC) 
activation. Tissue factor pathway inhibitor (TFPI) and protein S (PS) are released into blood. TFPI, after combining with factor Xa, 
binds to and neutralizes the TF/VIIa complex on cell surfaces. Protein S is the cofactor of activated protein C (APC) which degrades 
factors Va and VIIIa.  Micro-organisms and inflammatory mediators down-regulate the anticoagulant properties of the endothelium 
in different ways (see text).
clearly  suggested  by  the  observation  that  the 
selective  inhibition  of  TF  expressed  by  non-
hematopoietic  cells  substantially  reduces  the 
activation  of  coagulation  in  endotoxemic  mice.
69
The  precise  cellular  source  of  TF  in  the  non-
hematopoietic  cell  populations  is  unknown.  As 
mentioned  above,  in  endotoxemic  and  septic 
animals, TF expression is increased in many organs 
and cell  types.
61,63,64,67 Therefore, also considering 
that the role of EC TF remains uncertain, it is likely 
that TF up-regulation in multiple extravascular cell 
types in multiple organs contributes to activation of 
coagulation  during  sepsis.  Moreover,  the  well 
known  increase  in  vascular  permeability  and 
vascular  damage  occurring  during  severe 
inflammation  will  allow  the  exposure  of  normal 
extravascular TF to blood.
Overall,  at  least  in  the  setting  of  sepsis  and 
endotoxemia, monocytes-macrophages appear to be 
the main source of TF, together with specific cells 
in  target  tissues.  Further  support  for  a  prominent 
role of these cells comes from studies on MPs. In 
endotoxemic mice, levels of MP TF activity were 
found  to  correlate  with  coagulation  activation, 
suggesting the possible use of TF-positive MPs as a 
biomarker for evaluating the risk of DIC in Gram-
negative  sepsis.
81 Patients  with  meningococcal 
sepsis  had  increased  numbers  of  circulating 
procoagulant MPs derived from various cells with 
the  highest  levels  detected  in  a  patient  with  an 
extremely  fulminant  course  of  DIC.
82 The 
procoagulant  activity  of  MPs  was  due  to  the 
expression  of  both  TF  and  phosphatidylserine  on 
their surface and the majority of TF-positive MPs 
were  of  monocyte  origin  (CD14-positive). 
Interestingly,  the  formation  of  TF-positive 
procoagulant MPs derived from monocytes (CD14-
positive) has been also demonstrated in the model 
of human low-dose endotoxemia.
83
Impairment  of  physiological  anticoagulant 
mechanisms: Under  physiological  conditions  EC 
surface expresses various components involved in 
the  anticoagulant  pathways,  including 
thrombomodulin  (TM),  endothelial    protein  C 
receptor (EPCR), protein S, tissue  factor pathway 
inhibitor (TFPI) and the heparin like proteoglycan 
heparan  sulphate  (Figure 2).
33,84 EPCR  and Medit J Hemat Infect Dis 2010; 2(3): Open Journal System
Table 1. Inflammatory stimuli and conditions inducing tissue factor synthesis/expression in endothelial cells and/or mononuclear 
phagocytes.
thrombin  bound  to  TM  convert  protein  C  into 
activated  protein  C  (APC)  which  is  responsible, 
together  with  protein  S,  for  the  inactivation  of 
critical cofactors Va and VIIIa; TFPI, after binding 
factor Xa, complexes with TF-VIIa and blocks TF-
initiated  coagulation;  heparan  sulphate  stimulates 
the  inhibitory  activity  of  antithrombin  toward 
clotting  enzymes  like  thrombin  and  factor  Xa. 
Because  the  endothelium  plays  a  critical  role  in 
orchestrating the host response to sepsis and it is the 
target  of  the  pathogen  and  its  products,  and  of  a 
myriad of host mediators, a number of in vitro and 
in vivo studies evaluated the behavior of endothelial 
anticoagulant  mechanisms  in  relation  to  sepsis. 
Among these, the protein C anticoagulant pathway 
has  been  the  most  extensively  studied  and,  in 
general, it is down-regulated both in experimental 
and human sepsis. In vitro, the expression of TM 
was found consistently reduced in response to most 
agents listed in Table 1.
33,84
TM  reduction  has  been  attributed  to  different 
mechanisms  including  synthesis  inhibition, 
acceleration  of  internalization  and  degradation,  or 
inactivation  by  products  of  leukocytes  released
following  their  interaction  with  ECs,  such  as 
oxidants and/or lysosomal proteases.
33,84 Leukocyte 
proteases could also contribute to the release of TM 
from  the  cell  membrane.  Inflammatory  cytokines 
may  further  impair  the  protein  C  pathway  by 
reducing protein S secretion and the expression of 
EPCR in cultured ECs. Moreover, various agents, 
including  cytokines,  H2O2 and  thrombin 
dramatically increase the shedding of EPCR from 
cells in culture medium.
33,84
At  variance  with  in  vitro  studies,  animal 
experiments  investigating  in  vivo  changes  in  TM 
and  EPCR  produced  rather  controversial  data. 
While in one study
85 the infusion of IL-1 in rabbits 
suppressed  TM  activity  of  aortic  endothelium, 
down-regulation  of  TM  could  not  be  observed 
either  in  rabbit  aorta  during  experimental 
endotoxemia or in vascular beds of different organs 
in  two  distinct  sepsis  models  in  baboons  and 
rats.
64,86 On the other hand, a rise in soluble plasma 
TM was consistently observed during experimental 
endotoxemia, suggesting that direct and/or indirect 
(leukocyte-mediated) endothelial activation-damage 
by inflammatory mediators does occur in vivo.
33,87
As to the EPCR, studies in rats and mice showed 
that EPCR mRNA, rather than falling, as predicted 
from  in  vitro  experiments  with  cultured  cells, 
rapidly increased after treatment with lethal doses 
of LPS.
88 This was associated with a marked rise in 
soluble plasma EPCR. The increase of both EPCR 
mRNA  and  soluble  EPCR  was  mediated  by 
thrombin, not by TNF.
Although  the  data summarized above may  be 
difficult  to  interpret,  the  importance  of  the  PC 
anticoagulant pathway for the development of DIC 
in  sepsis  is  supported  by  animal  experiments 
showing that compromising the protein C system at 
different  levels  (by interfering with  PC activation 
through a monoclonal antibody or by reducing the 
plasma  levels  of  free  protein  S  with  the 
administration  of  C4b-binding  protein  or  by 
treatment with an antibody that blocked the binding 
of  EPCR  to  PC/APC)  resulted  in  a  marked 
worsening of DIC and in increased morbidity and 
mortality, whereas restoring an adequate function of 
APC  (by  treatment  with  APC)  prevented  the 
    Micro-organisms and derivatives
 Whole bacteria
 Rickettsiae and viruses
 Lipopolysaccharides (LPS)
 Peptidoglycan and lipotheicoic acid
 Staphylococcal and streptococcal exotoxins
 Shiga toxin (verotoxin-1)
 H. pylori-neutrophil activating protein
  Complement activation products
 C5a
 C5b-9
  Antibodies and immune complexes
  Bradykinin
  Cytokines
 Tumor necrosis factor-α (TNF-α)
 Interleukins (IL-1, IL-6)
 Interferon γ
       Chemokines
 Monocyte chemoattractant protein-1 (MCP-1)
 Interleukin-8
 Leukotactin-1
     Acute phase proteins
 C reactive protein (CRP), Long pentraxin
 α1-acid glycoprotein
     Growth factors (GF)
 Vascular endothelial GF (VEGF)
 Platelet-derived GF (PDGF)
 Monocyte colony-stimulating factor (M-CSF)
 GM-CSF
     Cell-cell interactions
     Clotting proteins (thrombin, factor Xa, fibrin)
     Hypoxia
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coagulopathy  and  improved  survival  and  organ 
failure.
1,11,33 Interestingly,  mice with  heterozygous 
protein  C  deficiency  had  more  severe  DIC  and 
organ dysfunction and a higher mortality than the 
wild-type  controls
89 and  mice  homozygous  for  a 
point  mutation  of  the  TM  gene  that  specifically 
deletes  the  anticoagulant  activity  of  the  protein 
(poor  binding  to  thrombin  and  thus  reduced 
capacity to generate APC), as compared with wild-
type mice, exhibited 10- to 30-fold greater amounts 
of fibrin in the microcirculation of several organs.
90
In  addition,  clinical  observations  indicate  that 
acquired severe protein C deficiency is associated 
with early death in individuals with sepsis.
91
Studies  in  human  sepsis  have  in  general 
confirmed    the  dysfunction  of  the  protein  C 
pathway.  The  plasma  levels  of  soluble  TM  were 
found to be increased
92-94 and were often correlated 
with disease  severity  and  poor  outcome.
92,94
Interestingly,  Saito  et  al.
95 found  significantly 
higher  TM  levels  in  septic  patients  with 
leukocytosis  than  in  those  with  leukopenia, 
suggesting an important role for leukocytes in EC 
perturbation. Patients with sepsis also had increased 
plasma levels of EPCR,
96 indicating that the latter 
can  be  used  as  an  additional  marker  of  EC 
activation. Other common findings in septic patients 
are low levels of PC and PS due to impaired liver 
synthesis and possibly to consumption (because of 
degradation by neutrophil elastase), and low levels 
of free PS, due to increased C4b-binding protein as 
a  consequence  of  the  acute  phase  reaction.
11,33
Moreover,  the  expression  of  TM  and  EPCR  on 
morphologically intact ECs of dermal vessels was 
found  to  be  reduced  in  biopsy  specimens  of 
purpuric lesions from children with meningococcal 
sepsis,  as  compared  with  control  skin-biopsy 
specimens.
93 Plasma  levels  of  APC  were  low  in 
some of these patients even after treatment with non 
activated PC  concentrates,  thus confirming down-
regulation of TM in vivo and impaired activation of 
protein  C.  Liaw  et  al.,
97 using  a  sensitive  assay, 
observed that plasma levels of APC vary markedly 
among  patients  with  severe  sepsis  and,  while  in 
some patients they paralleled thrombin generation 
(assessed  by  prothrombin  F1+2),  in  others  they 
were  low  despite  elevated  F1+2,  indicating  that 
APC  generation  is  impaired  in  the  latter. 
Interestingly, APC plasma levels were significantly 
higher in survivors  than in non survivors (28-day 
mortality), suggesting that endogenous APC serves 
protective  functions.  Indeed,  besides  exerting 
anticoagulant and profibrinolytic activity, APC also 
has  important  inflammation-modulating  effects, 
including  decreased  production  of  inflammatory 
cytokines  and  TF  by  activated  monocytes, 
antioxidant  properties,  anti-apoptotic  activity  and 
prevention of loss of endothelial barrier function.
98
During  sepsis,  plasma  antithrombin  levels  are 
markedly  decreased  because  of  consumption 
resulting from ongoing clotting activation, impaired 
synthesis and degradation by neutrophil proteases.
11
The  observation  that  inflammatory  stimuli  can 
down-regulate  the  expression  of  heparan  sulphate 
proteoglycan  in  cultured  ECs
1,33 suggests  an 
additional  mechanism  contributing  to  the  reduced 
antithrombin function in sepsis. Low antithrombin 
plasma levels have been found to be associated with 
increased mortality.
6
With respect to TFPI, in vitro studies evaluating 
the effect of inflammatory stimuli on the production 
of  this inhibitor by cultured ECs gave  conflicting 
data.
33 Likewise,  controversial  reports  have  been 
published on the changes of TFPI in plasma during 
sepsis, ranging from increased levels, probably due 
to release from ECs, to reduced, likely as a result of 
consumption,  or  unchanged  levels.
33 Deeper 
information  on  the  regulation  of  TFPI  by 
inflammatory  agents  have  been  obtained  from 
animal studies at tissue  and cellular level.  In rats 
given endotoxin and in mice given either TNF or 
endotoxin,  a  decreased  expression  of  TFPI  was 
found in several organs and in ECs.
65,99 Moreover, 
Tang  et  al.
100 found  that  lung-associated  TFPI 
antigen  and  mRNA  decreased  during  E.  Coli-
induced  sepsis  in  baboons,  and  TFPI  activity 
diminished  abruptly  as  soon  as  at  2  hours  after 
bacterial  challenge.  Blocking  antibodies  against 
TFPI  increased fibrin  deposition in septic baboon 
lungs,  suggesting  that  TF-dependent  coagulation 
might be aggravated by reduced endothelial TFPI. It 
can be concluded that TFPI under-expression might 
represent  an  additional  mechanism,  together  with 
TF up-regulation, to augment the local procoagulant 
potential, thus contributing  to fibrin formation at 
tissue level. The importance of TFPI in modulating 
the procoagulant response to endotoxin in vivo is 
supported  by  the  observation  that,  in  human 
experimental  low-dose  endotoxemia
101 and  in  a 
baboon E.coli sepsis model,
18 the administration of 
TFPI  inhibited  thrombin  generation  and,  in  the 
latter model, also reduced the mortality. This effect 
probably results not only from impaired coagulation 
but  also  from  the  capacity  of  TFPI  to  block  the 
cellular effects of endotoxin.
102
Suppression  of  fibrinolysis: In  sepsis-associated 
DIC  accumulation  of  fibrin  deposits  in  the 
microcirculation  may  be  greatly  facilitated  by  an 
impairment of the fibrinolytic system.
16,33 Infusion Medit J Hemat Infect Dis 2010; 2(3): Open Journal System
Figure 3. Fibrinolysis suppression in sepsis. Microorganisms, their products, and endogenous inflammatory mediators may lead to 
hypofibrinolysis by enhancing the release of plasminogen activator  inhibitors (mainly PAI-1), particularly by endothelial cells. The 
same agents may variably influence the release of t-PA (see text for further details).
of  des-A-fibrin  or  thrombin,  at  doses  unable  to 
induce  fibrin  accumulation  in  normal  animals, 
caused  diffuse  renal  microthrombosis  in  animals 
pretreated with antifibrinolytic agents. Interestingly, 
a single endotoxin injection was sufficient to render 
the animals sensitive to thrombogenic stimuli, most
probably because  of the inhibition  of fibrinolysis. 
Moreover,  administration of  high doses  of  tissue-
type plasminogen activator (t-PA) or low doses of 
plasminogen activator inhibitor-1 (PAI-1)-resistant 
t-PA  prevented  fibrin  deposition  in  kidneys  of 
endotoxin-treated rabbits.
33 Likewise, in a rat model 
of  endotoxemia,  fibrin  deposition  in  lungs  was 
decreased by an inhibitor of PAI-1.
33
Endothelium is known to play a pivotal role in 
the  fibrinolytic  process  through  the  regulated 
synthesis and release of key proteins, namely t-PA, 
urokinase-type  PA  (u-PA)  and  PAI-1.  The 
production of  these proteins  can  be  modulated in 
cultured ECs by a number of stimuli or conditions.
33
Among  the  agents  involved  in  sepsis-associated 
DIC,  some,  such  as  TNF,  IL-1,  LPS  and  herpes 
simplex  virus,  had no  effect  or  decreased  t-PA 
synthesis (Figure 3), while others, such as thrombin 
and  factor  Xa,  increased  t-PA  production.
33
However, most of the above stimuli, including those 
that augmented t-PA release, as well as many others 
listed  in  Table  1,  consistently  stimulated  PAI-1 
synthesis (Figure 3), the net effect being definitely 
antifibrinolytic.
33 It should be noted that, in cultured  
monocytes-macrophages,  inflammatory  mediators 
stimulated mainly the  synthesis of  PAI-2 (Figure
3).
16 Studies in non-human primates and in healthy 
volunteers  receiving  low-dose  endotoxin  or  TNF  
have  shown  a  sudden  increase  in  plasma  t-PA  
levels, indicative of EC activation, which coincided 
with  the  activation  of  the  fibrinolytic  system, 
assessed  by  augmented  plasmin-2-plasmin 
inhibitor  complexes.  However,  the  fibrinolytic 
activity was  rapidly  offset  by the  subsequent  and 
long-lasting increase in the plasma levels of PAI-
1.
11,33 A marked increase in plasma PAI-1 during 
endotoxemia has consistently been found in every 
animal  species.
33,103 Studies  at  tissue  level  in 
animals challenged with endotoxin or TNF showed 
a  strong  elevation  of  PAI-1  mRNA  in  tissues, 
including  those  most  commonly  affected  by 
microthrombi during sepsis (kidney, adrenals, lung 
and  liver).  PAI-1  expression  (RNA,  protein  or 
activity) was detected primarily in ECs at all levels 
of the vasculature (arteries, veins and capillaries).
33
The  up-regulation  of  PAI-1  synthesis  in  ECs  of 
multiple tissues clearly suggests that plasma PAI-1 
may originate from these cells during endotoxemia. Medit J Hemat Infect Dis 2010; 2(3): Open Journal System
In this respect, a possible contribution of platelets 
seems  unlikely  because  neither  thrombocytopenia 
nor  antiplatelet  agents  affected  the  increase  in 
plasma PAI-1 in rat endotoxemia.
33
Endotoxin  administration  also  causes  changes 
in t-PA and u-PA expression in rats and mice. In 
both animal species, an increase in t-PA mRNA was 
observed  in  different  tissues.
33 However,  this 
increase  was  not  associated  with  increased  t-PA 
activity, because of the very large amounts of PAI-1 
produced in the same tissues. u-PA mRNA behaved 
differently in rats and mice, being increased in rat 
kidney
104 but markedly decreased in murine tissues, 
particularly  in  adrenals  and  kidneys  (tubular 
epithelial cells).
105 Interestingly, the decrease in u-
PA expression correlated with fibrin deposition in 
kidneys and adrenals of endotoxin-treated mice.
106
In rabbits given a continuous infusion of endotoxin 
or TNF, a marked reduction in fibrinolytic activity 
was  observed  in  glomeruli  own  to  a  reduced 
production of PAs.
107 Altogether these data indicate 
that suppression of the fibrinolytic system through 
increased  PAI-1,  mostly  mediated  by  ECs,  and 
other  tissue- and  species-specific  alterations, such 
as decreased u-PA in the mouse model, are essential 
for fibrin deposition in tissue-specific vasculature, 
at  least  in  experimental  models  of  sepsis.  This 
concept  is  strongly  supported  by  experiments  in 
mice  with  targeted  disruptions  of  genes  encoding 
fibrinolytic  proteins.  Mice  with  a  deficiency  of 
plasminogen activators have more extensive fibrin 
deposition  in  organs  when  challenged  with 
endotoxin,  whereas  PAI-1  knockout  mice,  in 
contrast  to  wild-type  controls,  have  no 
microvascular  thrombosis  upon  endotoxin 
challenge.
106,108
Local  changes  in  fibrinolysis,  however,  may 
involve  also other  mechanisms.  Administration of 
low-dose  endotoxin  to  chimpanzees  caused  a 
marked  depression  of  fibrinolytic  activity  in  the 
bronchoalveolar  fluid,  due  to  increased  levels  of 
PAIs, especially PAI-2.
109 In this case, macrophages 
rather  than  ECs  were  more  likely  responsible  for 
down-regulating fibrinolysis. Similarly, in a mouse 
model of hypoxia, a clear increase in PAI-1 mRNA 
in  the  lung  tissue  was  observed,  which  was 
associated with a decrease in both t-PA and u-PA 
mRNAs.
33,108 These  local  changes  were  shown  to 
play an important role in hypoxia-induced vascular 
fibrin  deposition  in  the  lung.  Again, 
immunolocalization studies identified macrophages 
as  the  predominant  source  of  PAI-1  within  the 
hypoxic  lung.  Therefore,  the  cellular  origin  of
fibrinolytic  components  may  be  quite  different, 
depending on the tissue, the animal species, and the 
pathological condition.
In  human  sepsis-associated  DIC,  studies  of 
endothelial  fibrinolysis-related  properties  at  tissue 
level are scarce. In patients with adult respiratory 
distress syndrome (ARDS) secondary to sepsis, the 
fibrinolytic  activity  of  bronchoalveolar  fluid  was 
markedly lower than that of patients with interstitial 
lung  disease  or  normal  subjects,  due  to  the 
appearance of PAI activity.
33,110In situ hybridization 
on  lung  biopsies  showed  that,  like  in  animal 
models,  macrophages  rather  than  ECs  were  the 
main source of PAI-1. The majority of studies in 
patients  with  sepsis  has  been  restricted  to 
circulating fibrinolytic markers. In septic patients a 
sustained  increase  in  plasma  PAI-1  has  been 
consistently  reported  by  numerous 
investigators
33,103,111,112 and, in some studies, PAI-1 
turned out to be a prognostic marker in patients with 
septic shock.
33,111,112 Plasma t-PA antigen was also 
found to be elevated  in septic patients,
33 but the net 
effect  of  the  changes  in  t-PA  and  PAI-1  was 
definitely  antifibrinolytic.  That  impaired 
fibrinolysis  is  an  important  factor  in  the 
pathophysiology of  human  sepsis  is  supported by 
the finding that a 4G/5G polymorphism in the PAI-
1 promoter, leading to high PAI-1 expression, was 
associated  with  poor  outcome  in  meningococcal 
sepsis
11,33 and with multiple organ dysfunction and 
shock in pneumonia-induced severe sepsis.
113
During  the  last  decade  evidence  has 
accumulated  that  other,  thrombin-dependent 
mechanisms  may  contribute  to  the  impairment  of 
fibrinolysis  during  sepsis.  Besides  stimulating  the 
synthesis and release of fibrinolytic components in 
different cells, thrombin is able to affect fibrinolysis 
in  different  ways:  a)    it  stabilizes  the  clot  by 
activating  factor  XIII,  which  introduces  covalent 
bonds between fibrin strands and incorporates α2-
plasmin inhibitor  into  the clot;
114 b)  it causes  the 
formation of more compact and less permeable clots 
in  a  concentration-dependent  way;
115 and  c)  it 
reduces  plasmin  generation  via  activation  of 
thrombin-activatable  fibrinolysis  inhibitor  (TAFI) 
(procarboxypeptidase  U),  a  plasma 
procarboxypeptidase  that,  once  converted  into  the 
active  enzyme,  TAFIa,  removes  the  C-terminal 
lysines  from  partially  degraded  fibrin,  thereby 
reducing the binding of  t-PA and plasminogen to 
the  clot.
116 All  of  these  mechanisms  have  been 
associated with resistance to fibrinolysis.
In  sepsis,  enhanced  thrombin  generation 
induced by activated cells might well contribute to 
inhibition  of  fibrin  removal  by  the  fibrinolytic 
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the fibrin network and by activating TAFI. To our 
knowledge there are no available ex vivo studies on 
the  characteristics  of  fibrin  deposited  in  tissues 
during sepsis. Recently, however, Campbell et al.
117
reported  that  ECs  stimulated  by  inflammatory 
cytokines to  express TF,  similarly  to  normal  TF-
expressing extravascular cells (fibroblasts, SMCs), 
caused the  production  of  abnormally  dense  fibrin 
networks  that  resisted  fibrinolysis.  Moreover, 
activated platelets, commonly found in sepsis, not 
only  alter  the  fibrin  structure  and  reduce 
susceptibility  to  lysis  via  the  direct  interaction 
between  fibrin  and    αIIbβ3  integrin
117 but  also 
release, together with the causative micro-organism, 
inorganic polyphosphates, which have been recently 
shown  to  modify  the  fibrin  architecture  and  to 
reduce  the  binding  of  t-PA  and  plasminogen  to 
fibrin,  thereby  increasing  fibrin  resistance  to 
fibrinolysis.
118
With respect to TAFI, evidence is accumulating 
that it might be importantly involved in the sepsis-
associated  suppression  of  fibrinolysis.  In  vitro, 
LPS-stimulated  human  monocytes  inhibit 
fibrinolysis  through  a  tissue  factor-mediated 
enhancement  of  TAFI  activation  and  make  clots 
resistant  to  the  profibrinolytic  activity  of 
heparins.
119 Because  TF-expressing  monocytes-
macrophages  drive  blood  clotting  activation  in 
sepsis,  our  findings  provide  an  additional 
mechanism  whereby  these  cells  may  favor  fibrin 
accumulation in the microcirculation. Experiments 
in mice with targeted disruption of the TAFI gene 
did not allow clear-cut conclusions about the role of 
this  protein  in  endotoxemia.
120 However,  in  a  rat 
model  of  polymicrobial  sepsis,  a  significant 
reduction of TAFI levels was observed,
121 probably 
due  to  TAFI  consumption.  Moreover,  in  rat 
endotoxin-induced  DIC,  it  was  demonstrated  that 
blocking TAFIa with a synthetic inhibitor (BX528) 
attenuated  fibrin  resistance  to  endogenous 
fibrinolysis.
122 More recently, Muto et al.,
123 using a 
rat  endotoxemia  model  and  a  rat  sepsis  model 
induced by Pseudomonas aeruginosa, showed that 
the  administration  of  another  synthetic  TAFIa 
inhibitor  (EF6265)  1  and  2  hours  after  the 
intravenous  injection  of  LPS  and  bacteria, 
respectively, resulted in decreased fibrin deposition 
in the kidney and liver without significant changes 
in  platelet  count  and  plasma  fibrinogen  levels. 
Notably, this compound also significantly decreased 
laboratory  markers  of  organ  dysfunction  in  both 
models  and  the  inflammatory  response  in  the 
bacterial  infection  model.  In  a  baboon  model  of 
Escherichia  coli-induced  sepsis,  Binette  et  al.
124
demonstrated  that  TAFI  is  rapidly  activated  and 
cleared and that a monoclonal antibody specifically 
inhibiting thrombin-TM-dependent TAFI activation 
prevented  the  TAFI  activation/consumption  and 
enhanced the rate of fibrin degradation. Therefore, 
in  an  in  vivo  model  in  which  multiple  potential 
activators of TAFI are present (thrombin, plasmin, 
elastase),  thrombin-TM  appeared  to  be  the 
predominant  activator  and  the  generated  TAFIa 
down-regulated  fibrinolytic  activity.  In  human 
studies, TAFI levels (activity and/or antigen) were 
found  consistently  decreased  in  septic  patients  as 
well  as  in  healthy  volunteers  with  low-grade 
endotoxemia.
125-127 It  was  unclear  whether 
activation or consumption or both were the cause of 
this decrease. In a comprehensive study evaluating 
TAFI activation markers on a rather large series of 
patients  with  severe  meningococcal  infection, 
Emonts et al.
128 demonstrated that TAFI levels were 
significantly  decreased  at  admission  compared  to 
the convalescence state and were lower in patients 
with  septic  shock.  More  important,  the  levels  of 
TAFI  activation  peptide  (TAFI-AP)  were 
augmented in patients with DIC as compared with 
those  without.  In  addition  both  TAFI-AP  and 
inactivated  TAFIa  (TAFIai),  another  marker  of 
TAFI activation, were significantly higher in non-
survivors  versus  survivors  and strongly correlated 
with severity scores of the disease. It thus appears 
that TAFI activation does occur in severe sepsis and 
that  the measurement  of TAFI activation markers 
may  be  clinically  useful.  The  pathophysiological 
and clinical relevance of TAFI is further supported 
by  the  observation  that  a  functional  single 
nucleotide  polymorphism  in  the  TAFI  gene  that 
leads  to  the  substitution  Thr325Ile  and  produces 
increased  TAFIa  stability  and  activity  was 
associated with a poor outcome of meningococcal 
sepsis.
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Role  of  endogenous  inflammatory  mediators  in 
coagulation/fibrinolysis  changes: While  in  vitro 
the  pathogen,  its  derivatives  and  the  main 
inflammatory  mediators  are  able  to  influence  to 
variable extent each of  the mechanisms described 
above,  their  role  during  experimental  and  human 
sepsis or endotoxemia is more difficult to establish. 
With  respect  to the  up-regulation  of  procoagulant 
pathways,  various  inflammatory  mediators  are 
likely  involved,  besides  the  micro-organism  itself 
and  the  products  it  expresses  (for  instance 
endotoxin). The main cytokines, i.e. TNF, IL-1 and 
IL-6, can activate blood coagulation in humans and 
primates.
40 This occurs  most probably via the TF 
pathway,  although  direct,  definitive  proof  for 
induction of TF synthesis by these cytokines in vivo Medit J Hemat Infect Dis 2010; 2(3): Open Journal System
is  very limited.  As to the relative contribution  of 
individual  cytokines,  neutralization  studies  with 
specific antibodies would suggest a major role of 
endogenous IL-6 and, to a lesser extent, of IL-1.
40
Although  TNF  can  activate  coagulation  when 
injected in animals or in man and can induce TF in 
vitro, endogenous TNF does not appear to play a 
significant role in activation of coagulation during 
endotoxemia  or  gram-negative  sepsis.  Knowledge 
of the in vivo effects of cytokines on anticoagulant 
pathways is rather scarce. A neutralizing anti-TNF 
antibody attenuated the release of soluble TM into 
the  circulation  of  baboons  with  E.  Coli-induced 
severe  sepsis.
40 Moreover,  both  TNF  and  IL-1, 
when  administered  to  mice,  reduced    protein  C 
mRNA expression in liver and other organs.
40 As to 
the  fibrinolysis,  the  neutralization  of  endogenous 
TNF  activity  by  various  means  in  humans  or 
chimpanzees  almost  completely  prevented 
endotoxin-induced  fibrinolytic  changes,  including 
both t-PA and PAI-1 release.
40 Inhibition  of TNF 
has also been shown to down-regulate plasma PAI-
1  levels  in  a  clinical  setting  other  than  sepsis.
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Similar  effects  were  obtained  in  baboons  with 
severe  sepsis  following  the  administration  of 
recombinant  IL-1  receptor  antagonist.
40 In  mice 
challenged  with  endotoxin,  anti-TNF  treatment 
attenuated plasma PAI-1 increase and reduced PAI-
1  mRNA  expression  in  the  liver.
40 IL-1  and 
especially  TNF,  therefore,  appear  to  be  strongly 
involved  in  PAI-1-mediated  suppression  of 
fibrinolysis associated with sepsis. In a very recent 
comprehensive study using a baboon model of E. 
coli-induced  severe  sepsis,  Silasi-Mansat  et  al.
131
demonstrated  that  treatment  with  compstatin,  a 
potent  C3  convertase  inhibitor,  effectively 
attenuated  the  inflammatory  response  and  the 
associated  DIC,  and  improved  the  function  of 
several  organs  (heart,  kidney,  liver).  Compstatin 
decreased TF expression in lungs and other organs 
and  this  decrease  correlated  with  the  observed 
reduction in monocyte-macrophage infiltration. The 
reduced TF levels were accompanied by a reduced 
PAI-1 expression and by a protection against TFPI 
and  TM  down-regulation  in  ECs.  It  thus  appears 
that  complement-derived  mediators  play  an 
important role in the up-regulation of cell TF and 
PAI-1, and in the down-regulation of anticoagulant 
pathways during sepsis. Altogether, these findings 
clearly show that, as predicted by in vitro studies, 
inflammatory  stimuli  are indeed  able to  elicit  the 
main mechanisms responsible for in vivo thrombin 
generation and fibrin deposition during sepsis.
Pathogenetic  mechanisms  of  multiple  organ 
dysfunction syndrome (MODS)
MODS  is  the  hallmark  of  severe  sepsis  and 
septic shock and represents the main cause of the 
high mortality in these conditions. Various closely 
interlinked  mechanisms  have  been  proposed  to 
explain this dramatic event, all of which eventually 
result from the global hyper-inflammatory response 
to  the  triggering  pathogen.
132 In  the  early  phase, 
overproduction  of  numerous  cell-derived  (mainly 
cytokines) and soluble (e.g. complement activation 
products)  inflammatory  mediators causes 
widespread  activation/dysfunction  and  injury  of 
ECs  resulting  in  increased  vascular  permeability, 
prothrombotic  cell  surface  changes,  up-regulation 
of adhesion molecules with subsequent recruitment 
and  extravasation  of  polymorphonuclear  and 
mononuclear  cells.
132,133 Although  endothelial 
activation/dysfunction  is  generalized,  the  local 
susceptibility  to  endothelial  changes  can  vary 
widely  because  of  the  heterogeneity  of  EC 
properties  between  vascular  beds  in  different 
organs.
133 In the later phase of MODS, the recruited 
cells, together with other tissue cells, such as mast 
cells, release and produce a number of mediators, 
including cytokines, thus amplifying inflammation 
in the interstitial space.
132 The ensuing parenchimal 
cell injury and organ dysfunction is most likely due 
to  several  simultaneously  acting  mechanisms.  A 
critical role has been attributed to neutrophils owing 
to  their  inappropriate  positioning  within  the 
microvasculature  (because  of  endothelial 
dysfunction)  and  to  their  massive  activation  with 
subsequent release of reactive oxygen and nitrogen 
species  and  a  mixture  of  lytic  enzymes,  besides 
many  other  factors.
77 High  concentrations  of 
selected cytokines in the interstitial space might be 
directly toxic to vulnerable parenchyma and play a 
role  particularly  in  MODS  with  severe 
leukopenia.
132 The  complex  interplay  between 
inflammation  and  the  haemostatic  system  during 
sepsis  frequently  leads  to  DIC,  which  causes 
massive  fibrin  formation  and  its  persistent 
deposition in the microcirculation. Several lines of 
evidence  support  an  important  role  of  DIC  in 
MODS.
11 Numerous histological studies of tissues 
from  septic  patients  and  from  animals  with 
bacteremia    or  endotoxemia  have,  indeed, 
demonstrated the presence of thrombi in small and 
mid-size  vessels  of  multiple  organs.  These 
intravascular thrombi appear to be clearly related to 
organ  ischemia-necrosis  and  dysfunction. 
Moreover, in experimental studies, amelioration of 
DIC  by  various  interventions  improves  organ 
failure  and,  at  least  in  some  cases,  mortality.  In Medit J Hemat Infect Dis 2010; 2(3): Open Journal System
some studies, the attenuation of systemic activation 
of intravascular coagulation was clearly associated 
with removal of locally deposited fibrin which may, 
at least in  part, contribute  to the  improvement of 
organ function. Finally, DIC has been shown to be 
an independent predictor of organ dysfunction and 
mortality in patients with sepsis. 
Recent evidence indicates the existence of new 
players in sepsis-associated organ dysfunction and 
failure, namely extracellular histones, that originate 
mainly  from  apoptotic  or  necrotic  cells  and 
therefore  can  be  considered  as  late  mediators  of 
MODS. Histones are normal nuclear proteins that 
serve an essential architectural role by forming the 
core around which DNA is wrapped in eukaryote 
cells  and  contribute  to  gene  regulation.  These 
proteins  can  also  be  found  in  the  extracellular 
environment  where  they  kill  invading  pathogens 
thus  possibly  participating  in  the  innate  immune 
protection.  Recently  Xu  et  al.
14 have  shown  that 
histones  are  major  mediators  of  injury  during 
sepsis.  In  vitro  they  were  toxic  for  human 
endothelial cells and this toxicity was mainly due to 
the histones H3 and H4. When injected into mice, 
histones  mimicked  the  symptoms  of  sepsis, 
including  microvascular  thrombosis,  organ  failure 
and  death.  More  importantly,  antibodies  against 
histone  H4  protected  mice  in  different  models  of 
endotoxemia  and  sepsis.  A  remarkable finding  of 
the  study  is  that  recombinant  APC  was  able  to 
degrade  histones  both in  vitro  and  in  vivo  thus 
lowering the histone toxicity towards ECs in vitro 
and preventing lethality in histone-treated animals. 
Of note, histones and their APC-induced degraded 
forms were detected in plasma from septic animals 
and patients. Therefore histones add to the list of 
APC  substrates  that  make  this  protease  effective 
against  sepsis.  Interestingly,  histones  are  not  the 
only nuclear proteins involved in sepsis. HMGB1 is 
a  nuclear  DNA-binding  protein  involved  in 
nucleosome  stabilization  and  gene  transcription. 
However,  when  released  into  the  extracellular 
environment,  it  becomes  a  lethal  mediator  of 
systemic inflammation.
134 HMGB1 increases in the 
circulation in different animal models of sepsis as 
well as in septic patients. When injected in mice, 
HMGB1 is lethal and a recent study showed that it 
promotes  the  development  of  microvascular 
thrombosis  in  rats  likely  by  stimulating  TF 
expression  in  monocytes  and  by  reducing  the 
activity of thrombin-TM complex thereby inhibiting 
protein  C  activation.
39 Passive  immunization  with 
anti-HMGB1  antibody  confers  significant 
protection  against  lethal  endotoxemia,  sepsis  and 
LPS-induced  lung  injury,  even  when  antibody 
administration  is  delayed.
134 These  observations 
raise  the  possibility  that  nuclear  contents  in 
circulation  might  indicate  severe  damage  and 
contribute  to  host  mortality.  While  HMGB1  is 
known  to  be  released  actively  by  innate  immune 
cells  (monocytes-macrophages)  stimulated  by 
numerous  inflammatory  mediators  (including 
cytokines) and passively by necrotic cells, it is not 
yet clear where histones come from during sepsis. 
Neutrophils are an attractive possibility, as they are 
the most abundant white blood cells participating in 
severe  sepsis.
15 Furthermore,  platelets  activate 
neutrophils  to  make  neutrophil  extracellular  traps 
(NETs)  during  sepsis.
135 NETs  are  made  of 
chromatin, that is DNA and core histones. Although 
they  might  help  killing  micro-organisms  during 
sepsis,  they  may  also  lead  to  tissue  damage  and 
organ failure. A major source of histones is most 
probably  massive  cell  apoptosis  or  necrosis 
overwhelming  the  clearance  capacity  of 
mononuclear  phagocytes,  thereby  permitting 
histones to enter into circulation. Altogether, these 
results clearly demonstrate that histones are toxic to 
endothelium,  are released  during  sepsis  and  are 
important  mediators  of  sepsis  with  devastating 
effects. 
Concluding remarks
Considerable  progress  has  been  made  in  our 
knowledge  on  the  mechanisms  underlying  sepsis-
associated  DIC  and  MODS.  Although  direct 
interactions  between  the  infectious  agent  and  the 
haemostatic  system  do  occur,  the  numerous 
inflammatory  mediators  generated  by  the  host  in 
response  to  the  causative  micro-organism, 
particularly  cytokines  and  complement  activation 
products, are now believed to play a pivotal role in 
driving the major changes responsible for massive 
thrombin  formation  and  fibrin  deposition,  namely 
the aberrant  expression of the coagulation trigger 
TF  by  different  cell  types  (especially  monocytes-
macrophages)  and  the  impairment  of  both 
physiological  anticoagulant  mechanisms 
(antithrombin,  protein  C  pathway  and  TFPI)  and 
fibrinolysis,  mainly  due  to  inflammation-induced 
endothelial dysfunction. The ensuing thrombosis in 
the  microcirculation  and  ischemia  are  generally 
thought  to  contribute  to  parenchimal  cell 
injury/death  and  single  or  multiple  organ 
dysfunction,  together  with  other  rather  well-
established  mechanisms,  also  elicited  by  the 
overwhelming  inflammatory  response,  such  as 
neutrophil- and  macrophage-derived  factors  and 
selected  cytokines with  direct  toxic  effects.  The 
recently  published  evidence  that  extracellular Medit J Hemat Infect Dis 2010; 2(3): Open Journal System
histones,  particularly  H3  and  H4,  “are  major 
mediators  of  death  in  sepsis”
14 add  to  our 
understanding  of  the  MODS  pathogenesis.  These 
nuclear  proteins,  together  with  others  such as 
HMGB1, are released into the circulation mainly by 
apoptotic or necrotic cells and thus may represent 
late  mediators  that  amplify  inflammation, 
coagulation, cell death and organ failure.
Whether  the  present  knowledge  on  the 
pathogenesis of sepsis-associated DIC and MODS 
will  prove  useful  for  diagnostic  and  therapeutic 
purposes remains to be established. The diagnosis 
of DIC is still based on the combination of a typical 
underlying disease, such as sepsis, with laboratory 
markers, including platelet count, prothrombin time, 
activated  partial  thromboplastin  time,  fibrinogen 
concentration,  and  a  fibrin-related  marker, 
reflecting intravascular fibrin formation, such as D-
dimer, all of which are used in the DIC scores.
11
However,  new  parameters  are  being  investigated 
that  could  be  of  clinical  utility.  For  instance, 
HMGB1  is  persistently  augmented  in  septic 
patients, being significantly higher in non survivors 
than in survivors and the plasma concentration of 
this  protein  has  been  proposed  as  possible 
prognostic  markers  of  DIC  and  organ  failure.
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Moreover,  elevated plasma  levels  of  nucleosomes 
have  been  reported  in  septic  patients  that  were 
proportional to the disease severity (highest values 
in septic shock)
137,138 and single histones H3 and H4 
were  increased in  patients  with  severe  sepsis.
14
Nuclear proteins, therefore, might be new sensitive 
biomarkers  of  disease  progression  and  useful 
predictors of outcome.
As regards the supportive treatment for sepsis-
associated  haemostatic  abnormalities,  different  
strategies  have  been  developed  based  on  the 
insights  into  the  pathogenetic  mechanisms 
responsible  for  thrombin  formation  and  fibrin 
deposition.  However,  the  use of  TF  inhibitors, 
which  would  be  the  most  logical  treatment 
considering the widely accepted pivotal role of TF 
in blood clotting activation during sepsis, is still a 
matter of debate. A phase III trial with recombinant 
TFPI  did  not  show  a  overall  survival benefit  in 
septic  patients.
139 Likewise,  treatment  with 
antithrombin concentrates to restore one of the most 
important  anticoagulant  mechanisms  shown  to  be 
impaired in sepsis, despite some reported beneficial 
effects  (improvement  of  laboratory  parameters,
shortening of DIC duration, amelioration of organ 
function),  in  a  large-scale  clinical  trial  failed  to 
significantly  reduce  the  mortality  of  septic 
patients.
140 So  far,  the  only  anticoagulant  drug 
showing  the  expected  promising  results  is 
recombinant human APC, which has been evaluated 
in  several  clinical  trials  and  is  indicated  for  the 
reduction of mortality in adult patients with severe 
sepsis at high risk of death.
1 The beneficial effects 
of  this  drug  have been  attributed  not  only to  the 
restoration of the protein C anticoagulant pathway, 
which  is  strongly  impaired  in  septic  patients,  but 
also to its well-known anti-inflammatory action.
84,98
The finding that APC degrades histones
14 add a new 
mechanism  whereby  the  drug  exerts  it  beneficial 
effects especially in severe sepsis. Because histones 
seem to be critical mediators of organ dysfunction 
and death in septic patients, an attractive approach 
to  treat  MODS  and  prevent  death  could  be  the 
development of effective histone antagonists which 
might  prove  therapeutic  without  the  bleeding 
complications that can result from APC therapy. 
Finally, the  recent evidence that  complement-
coagulation  interplay  strongly  contributes  to  the 
progression  of  severe  sepsis
131  suggests  that 
blocking  the  harmful  effects  of  complement 
activation  products,  especially  during  the  organ 
failure  stage  of  severe  sepsis,  is  yet  another 
potentially important therapeutic strategy.
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